

Oesophago-gastric cancer committee meeting 8

Date: 30th and 31st January 2017

Location: RCOG, London

Minutes: Final

Committee members present:		
Mr Cyrus Kerawala		(Present for notes 1 – 8)
Mark Harrison		(Present for notes 1 – 8)
David Brooks		(Present for notes 1 – 8)
Hugh Burnett		(Present for notes 1 – 8)
David Simpson		(Present for notes 1 – 8)
Mimi McCord		(Present for notes 1 – 8)
Venetia Wynter-Blyth		(Present for notes 1 – 8)
Orla Hynes		(Present for notes 1 – 8)
Robert Willert		(Present for notes 6 – 8)
Andrew Bateman		(Present for notes 1 – 8)
Naureen Starling		(Present for notes 1 – 8)
David Exon		(Present for notes 1 – 8)
Nick Maynard		(Present for notes 1 – 8)

In attendance:		
Katie Perryman-Ford	NICE Guideline Commissioning Manager	(Present for notes 1 – 5)
Matthew Prettyjohns	NGA Senior Health Economist	(Present for notes 1 – 8)
May Oo Khin	NGA Systematic Reviewer	(Present for notes 1 – 8)
Amy Burt	NGA Assistant Reviewer	(Present for notes 1 – 5, 7, 8)
Abigail Moore	NGA Assistant Reviewer	(Present for notes 1 – 8)
Katrina Blears	NGA Project Manger	(Present for notes 1 – 8)
Hilary Eadon	NGA Guideline Lead	(Present for notes 1 – 8)
Nathan Broman	NGA Senior Systematic Reviewer	(Present for notes 1 – 8)

Observers:

None

Apologies:

Robert Willert had sent apologies for Day 1; Katie-Perryman-Ford gave apologies for Day 2

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the 8th meeting on Oesophago-gastric cancer.

No members of the public asked to observe the meeting.

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was Oesophago-gastric cancer.

Naureen Starling made a new declaration of interest:

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Naureen Starling	Consultant Medical Oncologist in GI Cancers & Associate Director of Clinical Research, The Royal Marsden	Nov 2016: Attended immuno-oncology summit in Washington DC. Travel and accommodation paid for by Roche. Drugs discussed were immunotherapy – atezolizumab.	Financial personal, non-specific	Declare and participate. Atezolizumab is not being discussed in this guideline.
Naureen Starling	Consultant Medical Oncologist in GI Cancers & Associate Director of Clinical Research, The Royal Marsden	Jan 2017: Gave lecture on management of gastric cancer at 2017 ECCO meeting in Amsterdam. Paid by Elsevier who had received a grant from Eli-Lilly. Eli-Lilly produce ramucirumab.	Financial personal, non-specific	Declare and participate. Ramucirumab is not being discussed in this guideline.

3. Minutes of last meeting

The minutes of the last meeting were agreed as a true and accurate record of the

meeting.
4. Presentations – Day 1
<p>The Chair introduced Amy Burt, who gave a presentations on the clinical evidence for topics 4.8, 1.1 and 1.2.</p> <p>The Chair introduced Matthew Prettyjohns, who gave a presentation on the health economic plan for topics 3.1 and 3.2.</p>
5. Questions and discussion – Day 1
<p>The Committee discussed and agreed the draft recommendations for topic 4.8, 1.1 and 1.2.</p> <p>The Committee discussed the draft health economic model for topic 3.1 and 3.2 and agreed that a model was only needed for 3.1</p>
6. Presentations – Day 2
<p>The Chair introduced May Oo Khin, who gave a presentations on the clinical evidence for topic 4.5</p> <p>The Chair introduced Nathan Bromham, who gave a presentations on the clinical evidence for topics 4.7</p> <p>The Chair introduced May Oo Khin, who gave a presentations on the clinical evidence for topic 4.1</p>
7. Questions and discussion – Day 2
<p>The Committee discussed and agreed the draft recommendations for topic 4.5</p> <p>The Committee discussed the draft health economic model for topic 4.5 and agreed changes.</p> <p>The Committee discussed and agreed the draft recommendations for topic 4.7 and 4.1.</p> <p>The committee reviewed the edited recommendations for topics 2.1, 4.4, 4.6 and 4.9.</p> <p>The LETRs for 2.2 and 4.6 were also reviewed and revised.</p>
8. Any other business
No service user or carer concerns were raised.

Date of next meeting: 23rd and 24th March 2017

Location of next meeting: RCOG, London